fbpx Announcing the Packaging Design QuickFire Challenge: Unit Dose Technologies - News | JLABS

Announcing the Packaging Design QuickFire Challenge: Unit Dose Technologies

July 28, 2021 -
2 months ago
Other news

July 28, 2021 - To inspire innovators to bring potentially groundbreaking unit dose packaging options to the market – with a focus on child-resistant, user-friendly, non-reclosable designs - Johnson & Johnson Innovation together with the packaging innovation team within Johnson & Johnson Consumer Inc. is launching the Packaging Design QuickFire Challenge: Unit Dose Technologies. Potential innovations can include both solids (tablets, capsules and powders) and liquids (solutions and suspensions) in unit-dose formats (e.g. blisters, sachets and stick packs). Primary and secondary packaging or combination of the two are in scope of the challenge.

As the science and innovation behind products evolve, so must the packaging of those products. Advancing additional options for unit dose packaging may represent the next generation of medication storage.

In the US, the wider adoption of non-reclosable unit dose packaging has been limited due to concern for user-friendly access and design [1], non-recyclable packaging waste, manufacturability and speed at which packaging lines can operate [2]. In addition to helping to prevent accidental unsupervised ingestions (AUIs) of medications by children, some unit dose packaging configurations have also shown to increase medication adherence [3], improve monitoring [4], and reduce risk of contamination [5].

The innovator(s) with the best idea, potential technology, or potential solution will receive grant funding from a total pool of up to $100,000, access to the global Johnson & Johnson Innovation – JLABS network and mentorship from experts across the Johnson & Johnson Family of Companies.*

The QuickFire Challenges are managed by Johnson & Johnson Innovation, with the goal to help address today’s greatest health care challenges.

* Subject to the execution of the necessary documentation and (award) agreements

About Johnson & Johnson Innovation

Johnson & Johnson Innovation LLC works across the pharmaceutical, medical device and consumer health sectors to accelerate early-stage, transformational solutions by catalyzing the best ideas, wherever they are in the world. We do this by harnessing our deep scientific capabilities coupled with a wide range of tools, including customized deal structures, company creation, incubation and startup services, capital investments and other innovative business models that aim to meet the diverse needs of entrepreneurs, scientists and emerging companies. Our goal is to help life science and health technology innovations thrive through collaboration and partnership with the global ecosystem, so that together we can change the trajectory of human health. Meet our passionate team of science and technology experts and learn how to collaborate with us at www.jnjinnovation.com.

About Johnson & Johnson Consumer Inc.

At Johnson & Johnson Consumer Health, we are driven to improve the personal health of people everywhere. Our differentiated portfolio of iconic brands, including Tylenol®, Zarbee's®, Neutrogena®, Aveeno®, Listerine®, OGX®, and Johnson's®, delivers life-enhancing, first-to-market innovation. By combining the power of science with meaningful human insights and digital-first thinking, we help more than 1.2 billion people live healthier lives every day, from their very first day.

[1] Problems experienced by older people when opening medicine packaging, The International journal of pharmacy practice, September 2013. Ghilbert, Notenboom, Bouvy, Geffen. https://www.researchgate.net/publication/256500034_Problems_experienced_by_older_people_when_opening_medicine_packaging

[2] Schneider PJ. The Impact of Technology on Safe Medicines Use and Pharmacy Practice in the US. Front Pharmacol. 2018;9:1361. Published 2018 Nov 20. doi:10.3389/fphar.2018.01361 Schneider PJ. The Impact of Technology on Safe Medicines Use and Pharmacy Practice in the US. Front Pharmacol. 2018;9:1361. Published 2018 Nov 20. doi:10.3389/fphar.2018.01361

[5] Pharmaceutical Commerce, " Pandemic’s drug-administration risks spotlight benefits of unit dose packaging. ” Michael Christel, January 2021.


Related content